Vitrafy Life Sciences Limited (ASX:VFY)

Market Cap	184.53M +124.0%
Revenue (ttm)	2.34M +51.9%
Net Income	-14.15M
EPS	-0.22
Shares Out	63.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,330
Open	2.890
Previous Close	2.890
Day's Range	2.740 - 2.890
52-Week Range	1.160 - 2.900
Beta	n/a
Analysts	Strong Buy
Price Target	2.70 (-1.46%)
Earnings Date	Apr 28, 2026

About Vitrafy Life Sciences

Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. The company offers smart devices, such as smart cryopreservation, smart thawing, and smart packaging devices. It also provides a software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials under the LifeChain brand. The company’s cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquaculture and bovine breeding p...

• Industry: Laboratory Apparatus and Furniture
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: VFY

Financial Performance

In fiscal year 2025, Vitrafy Life Sciences's revenue was 1.05 million, a decrease of -49.14% compared to the previous year's 2.06 million. Losses were -32.71 million, 213.8% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for VFY stock is "Strong Buy." The 12-month stock price target is $2.70, which is a decrease of -1.46% from the latest price.

Price Target

$2.70

(-1.46% downside)

Analyst Consensus: Strong Buy